Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Cavallo AL"'
Autor:
ILLARIO, MADDALENA, MARZANO, LUIGI ANTONIO, TRONCONE, GIANCARLO, FENZI, GIANFRANCO, ROSSI, GUIDO, VITALE, MARIO, CAVALLO AL, MONACO S, DI VITO E, MUELLER F
We recently demonstrated in an immortalized thyroid cell line that integrin stimulation by fibronectin (FN) simultaneously activates two signaling pathways: Ras/Raf/MAPK kinase (Mek)/Erk and calcium Ca2+/calcium calmodulin-dependent kinase II (CaMKII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3730::150822db6b49ae68daa61664517d1c9f
http://hdl.handle.net/11588/110246
http://hdl.handle.net/11588/110246
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
K. Ulrich Bayer, Guido Rossi, Anna Lina Cavallo, Mario Vitale, Tiziana Di Matola, Gianfranco Fenzi, Maddalena Illario
Publikováno v:
The Journal of biological chemistry. 278(46)
Integrin activation generates different signalings in a cell type-dependent manner and stimulates cell proliferation through the Ras/Raf-1/Mek/Erk pathway. In this study, we demonstrate that integrin stimulation by fibronectin (FN), besides activatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bab590daf17847e0c6e20bb043e9a177
https://pubmed.ncbi.nlm.nih.gov/12954639
https://pubmed.ncbi.nlm.nih.gov/12954639
Autor:
Starnes L; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Hall A; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Etal D; Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Cavallo AL; Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Grabowski P; Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Gallon J; Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Kha M; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Hicks R; BioPharmaceuticals R&D Cell Therapy Department, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.; School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, United Kingdom., Pointon A; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2024 Jul 08; Vol. 11, pp. 1357315. Date of Electronic Publication: 2024 Jul 08 (Print Publication: 2024).
Autor:
Chandrasekaran V; Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081, HZ, Amsterdam, The Netherlands., Carta G; Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081, HZ, Amsterdam, The Netherlands., da Costa Pereira D; Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081, HZ, Amsterdam, The Netherlands., Gupta R; Department of Toxicogenomics, Maastricht University, School of Oncology and Developmental Biology (GROW), Maastricht, The Netherlands., Murphy C; Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081, HZ, Amsterdam, The Netherlands., Feifel E; Institute of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, Austria., Kern G; Institute of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, Austria., Lechner J; Institute of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, Austria., Cavallo AL; Discovery Sciences R&D, AstraZeneca, Gothenburg, Sweden., Gupta S; Discovery Sciences R&D, AstraZeneca, Gothenburg, Sweden., Caiment F; Department of Toxicogenomics, Maastricht University, School of Oncology and Developmental Biology (GROW), Maastricht, The Netherlands., Kleinjans JCS; Department of Toxicogenomics, Maastricht University, School of Oncology and Developmental Biology (GROW), Maastricht, The Netherlands., Gstraunthaler G; Institute of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, Austria., Jennings P; Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081, HZ, Amsterdam, The Netherlands. p.jennings@vu.nl., Wilmes A; Division of Molecular and Computational Toxicology, Department of Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081, HZ, Amsterdam, The Netherlands. a.wilmes@vu.nl.
Publikováno v:
Scientific reports [Sci Rep] 2021 Jun 02; Vol. 11 (1), pp. 11575. Date of Electronic Publication: 2021 Jun 02.